ESC Premium Access

Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate

Congress Presentation

About the speaker

Associate Professor Michael Blazing

Duke Clinical Research Institute, Durham (United States of America)
1 presentation
0 follower

5 more presentations in this session

Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study

Speaker: Professor S. Yamashita (Izumisano, JP)


A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C

Speaker: Doctor S. Shah (Rahway, US)


Clinical tolerability and safety profile of CER-001, a novel bio-engineered pre-beta HDL-mimetic, across the clinical development programs

Speaker: Professor A. Corsini (Milan, IT)


Effect of pcsk9 antibodies on neurocognitive outcomes and improved survival in patients at higher risk: a meta-analysis of randomised controlled trials

Speaker: Doctor M. Kolodziejczak (Bydgoszcz, PL)


Dose-response relationship between proton pump inhibitor use and associated risk of myocardial infarction: a nationwide cohort study

Speaker: Doctor T. Sehested (Copenhagen, DK)


Access the full session

Lipid-lowering agents - New perspectives

Speakers: Associate Professor M. Blazing, Professor S. Yamashita, Doctor S. Shah, Professor A. Corsini, Doctor M. Kolodziejczak...

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by